Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Using Data and Asset-Management Solutions to Create Efficiencies in Healthcare and Eliminate Waste

In this episode of I Don't Care, host Kevin Stevenson speaks with Ashlea Souffrou, founder of SxanPro, about how data-driven asset-management solutions can help hospitals reduce medical waste and recover costs. U.S. hospitals lose significant revenue on unused medical equipment, and SxanPro's tools — Judi, Sam, and Link — provide inventory visibility and enable product reallocation across healthcare facilities. The conversation highlights the broader push for medical device sustainability in an industry generating over 5 million tons of waste annually.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

By Kevin Stevenson · Ashlea SouffrouAsset-management SolutionsHealthcare SolutionsI Don't Care Podcast
Share

Key takeaways

01

U.S. hospitals generate approximately 29 pounds of waste per bed daily, much of it from unused medical supplies and equipment.

02

SxanPro's solutions (Judi, Sam, and Link) give hospitals visibility into unused inventory, enabling cost recovery through reallocation or transfer.

03

Ashlea Souffrou transitioned from a sales role at Stryker to founding SxanPro, driven by a mission to reduce hospital waste and improve operational efficiency.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Asset-management solutions utilizing data to drive decision-making could prove a winning strategy in reducing medical waste in healthcare and saving money.

Asset-management solutions utilizing data to drive decision-making could prove a winning strategy in reducing medical waste in healthcare and saving money.

As healthcare systems worldwide strive to optimize their operations, the issue of medical device sustainability and waste reduction has taken center stage. With U.S. hospitals reportedly losing multi-thousands of dollars on unused medical equipment, state-of-the-art inventory, and asset-management solutions are more pressing than ever. On average, hospitals generate 29 pounds of waste per bed daily and more than 5 million tons annually. A significant portion of this waste comes from unused medical supplies and equipment.

How can hospitals better manage their inventory, reduce waste, and save costs?

Welcome to I Don't Care with Kevin Stevenson. In this episode, Stevenson welcomes guest Ashlea Souffrou, the Founder and President of SxanPro, a company dedicated to helping hospitals reduce waste and save money through innovative inventory management solutions.

In this episode, Stevenson and Souffrou discuss the following:

  • Souffrou's journey from a sales division employee at Stryker to the founder of SxanPro
  • How SxanPro addresses the problem of medical waste in hospitals
  • An in-depth look at SxanPro's innovative solutions: Judi, Sam, and Link

Ashlea Souffrou is a visionary leader in the medical device sustainability space. She started her career at Stryker, a leading medical technology company, right out of college. Her passion for helping hospitals reduce costs and recover waste led her to establish SxanPro. With her deep understanding of the challenges hospitals face in managing their inventory, she has led SxanPro to develop solutions that provide visibility into products that hospitals aren't using, helping them reallocate dollars and transfer those products to other sites or hospitals that may need them. Her innovative approach to tackling medical waste has made her a respected figure in the industry.

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Kevin Stevenson
Kevin StevensonTop Hospital Administrator & Healthcare COO, I Don't Care
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

Kevin Stevenson
Kevin Stevenson

Host, I Don't Care Podcast

I Don't Care

Kevin Stevenson is the host of the I Don't Care podcast on MarketScale, focused on the healthcare industry. He interviews executives and administrators who support hospitals, urgent care centers, and telemedicine operators with logistics and operations. Stevenson holds an MBA and FACHE designation.

AS
Ashlea Souffrou

Founder and President

SxanPro

Ashlea Souffrou is the founder and president of SxanPro, a company that helps hospitals reduce medical waste and save costs through innovative inventory and asset-management solutions. She began her career at Stryker, a leading medical technology company, before launching SxanPro to address unused medical equipment and supply waste in hospital systems. Her work focuses on providing visibility into underutilized products and facilitating their reallocation or transfer across healthcare sites.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512